uniQure (QURE)
(Real Time Quote from BATS)
$5.66 USD
+0.10 (1.80%)
Updated Nov 5, 2024 12:52 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
QURE 5.66 +0.10(1.80%)
Will QURE be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QURE
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Select Medical (SEM) Q3 Earnings and Revenues Surpass Estimates
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Other News for QURE
uniQure NV Q3 2024 Earnings: EPS Loss of $0.91 Beats Estimates, Revenue of $2. ...
uniQure GAAP EPS of -$0.91 beats by $0.03, revenue of $2.29M misses by $4.77M
uniQure reports Q3 EPS (91c), consensus ($1.01)
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
State Street Corp's Strategic Reduction in uniQure NV Holdings